

TENNESSEE GENERAL ASSEMBLY  
FISCAL REVIEW COMMITTEE



**FISCAL NOTE**

**SB 1765 - HB 1856**

February 19, 2016

**SUMMARY OF BILL:** Establishes that it is not a violation for a physician or osteopathic physician to prescribe, order, sell, or otherwise distribute lisdexamfetamine dimesylate for its currently accepted medical use in the United States. This law would supersede current rules of the Board of Medical Examiners.

**ESTIMATED FISCAL IMPACT:**

**NOT SIGNIFICANT**

Assumptions:

- Lisdexamfetamine dimesylate, known under its U.S. brand name of Vyvanse is a drug used to treat attention deficit hyperactivity disorder (ADHD) in adults and children six years of age or older. This medicine is also used to treat severe binge eating disorders.
- This legislation will have no direct, significant fiscal impact to current drug prescriptions as managed by the respective pharmacy benefit managers of healthcare plans managed by the Division of Benefits Administration or TennCare.
- The Board of Medical Examiners can make necessary rule changes during regularly scheduled board meetings.
- Pursuant to Tenn. Code Ann. § 4-29-121, all health related boards are required to be self-supporting over any two year period. The Board of Medical Examiners had a deficit of \$75,431 in FY13-14, a surplus of \$359,446 in FY14-15, and a cumulative reserve balance of \$2,725,411 on June 30, 2015.

**CERTIFICATION:**

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in blue ink that reads "Krista M. Lee".

Krista M. Lee, Executive Director

/jdb

**SB 1765 - HB 1856**